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A recent observational study conducted in Australia reports that patients with stroke who are recruited to clinical research studies received better hospital care than patients who were not included in research studies, and their in-hospital mortality was markedly lower 1 . Given the large volume of negative clinical studies in stroke and other neurological conditions, and the fact that some studies suggest participation in trials increases patients' risk of harm, accurately informing volunteers of the potential effects of a trial requires the best possible evidence base. The report by Purvis et al. 1 highlights the need for expanding this evidence, so as to improve support for patients when they are deciding whether or not to participate in clinical trials in any therapeutic area.
We rely on clinical research, particularly randomized trials, to provide the best evidence for clinical practice across health care settings. However, it is important that potential research participants are provided with adequate information about the risks and benefits of participating in studies to ensure that consent is informed and the risk of coercion is avoided. A common assumption is that taking part in clinical studies benefits all patients because, regardless of the intervention they receive, participation increases the likelihood that they will be provided with protocol-based care and frequent follow-up consultations, so that complications will be identified earlier. These assumed benefits are 13% were rehabilitation studies. No information was collected on whether studies were randomized trials or observational studies.
An individual medical case note audit of 9,537 patients at 129 hospitals found that only 469 patients (5%) consented to participate in research. Comparison of the care received by research participants and non-participants revealed significant differences in the proportions of patients who received several aspects of care: admission to a stroke unit (83% of participants versus 57% of non-participants); an early swallow screening test (62% versus 56%); early therapist review (73% versus 64%); and thrombolysis (18% versus 5%). When outcomes were adjusted for characteristics of hospitals (urban or rural, number of admissions for stroke) and patients (demographics, vascular risk factors, stroke severity), recruitment to research was independently associated with a marked reduction in in-hospital mortality (adjusted OR 0.30, 95% CI 0.12-0.76), but not with a reduction in disability or discharge home from hospital. The effect on mortality persisted when adjustments were made for admission to a stroke unit and receipt of thrombolysis. The authors concluded that patients who participated in stroke research received better in-hospital care, and were more likely to survive to the point of discharge from hospital than were patients who did not participate in research.
The results of this study must be interpreted with caution for several reasons. The allocation of patients to participate or not participate in research was not randomized, so the association of participation with improved care and outcomes might not indicate a causal relationship. For example, admission to a stroke unit, which was associated with a higher likelihood of participation in research, is likely to be the reason for better care rather than research participation per se.
In addition, despite the fact that corrections were made for known confounders, the apparent in-hospital mortality could be reduced owing to incomplete correction for stroke severity or unmeasured confounders. For example, additional confounding could result from timings of patient recruitment, variable lengths of stay, study types, the specific intervention and dropout rates, and additional unmeasured comorbidities, patient education level or socioeconomic factors. known as the 'trial effect' . However, surprisingly little evidence supports this assumption 2, 3 . Moreover, some evidence suggests that involvement in a clinical trial -particularly early phase intervention studies or those that involve invasive procedures -can increase the risk of harm. For example, the Albumin in Acute Stroke (ALIAS) trial was stopped early owing to futility in relation to the primary endpoint (reduced disability) and an increased risk of pulmonary oedema, atrial fibrillation and symptomatic intra cerebral haemorrhage among the albumin-treated participants 4 . Similarly, the Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) was stopped early because of worse outcomes in the surgical intervention group than in the control group 5 .
To determine whether participation in clinical research leads to better quality of care and better patient outcomes, Purvis et al. 1 used data from a National Stroke Foundation Acute Services Audit Program, in which cycles were conducted in 2009, 2011 and 2013. This voluntary program included a self-reported organizational stroke audit that identified all clinical research activity at Australian hospitals that involved patients with stroke. Unsurprisingly, involvement in research studies was greatest at hospitals with a stroke unit and with >200 admissions for stroke. 54% of the studies were in acute stroke (recruitment within 48 h of admission), 18% were secondary prevention studies, and
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A recent observational study showed that patients with stroke who participated in clinical research received better care and had lower mortality than patients who did not participate. However, the study has several limitations, and the available evidence suggests that patients should not be advised that participation in research improves outcomes.
Furthermore, despite the fact that the associations remained after corrections for admission to stroke units, the number of patients who were recruited to studies and were not admitted to a stroke unit was relatively small (79 individuals). It is therefore reasonable to assume that residual confounding is a factor, and that patients who are admitted to a stroke unit are more likely to both be recruited to research studies and also survive.
The effect of participation in research on inpatient mortality seems implausibly large. The observed 70% reduction in the odds of death is much larger than that seen with any other acute stroke intervention besides hemicraniectomy for malignant cerebral infarction 6 . The adage 'if a result is too good to be true, it is generally not true' might apply here. Furthermore, the beneficial effect was not seen on other important outcomes, such as independent function at discharge from hospital, or discharge home itself. This discrepancy could mean that the effect was due to a combination of bias and chance.
Finally, it is important to review this study in light of all other available evidence. A Cochrane review 7 has compared the outcomes of patients who participated in randomized controlled trials and patients who received similar treatment outside the trial. Despite considerable heterogeneity, no overall signifi cant differences were found in 85 of the 98 comparisons. Just eight comparisons revealed significantly better outcomes with trial participation, and five revealed significantly worse outcomes. Another systematic review and meta-analysis looked at outcomes of patients who had the same diagnoses but either entered randomized controlled trials ('insiders') or did not ('outsiders'). The analysis identified 147 studies that reported health outcomes of 'insiders' and a parallel or consecutive group of 'outsiders' within the same time period, and found no clinically or statistically significant differences between the outcomes of 'insiders' and 'outsiders' in most of the studies 8 : 'outsiders' experienced significantly worse health outcomes in only nine heterogenous studies in which 'insiders' received an effective intervention (mean difference −0.36, 95% CI −0.61 to −0.12).
On the basis of all the available evidence, participation in randomized controlled trials is, therefore, generally associated with outcomes that are similar to those with the same treatment outside trials, implying no substantial risk or benefit. We believe that, given the limitations of the study by Purvis et al. 1 , this conclusion stands even for stroke research, and that patients with stroke should not be told that taking part in clinical research will improve their outcomes.
Nevertheless, further research in this area is warranted. Exploration of other large, well characterized (in terms of baseline prognostic factors, treatments and outcomes) registries of patients with stroke might help to determine whether the results of the study by Purvis et al. are replicable. Without randomization, however, establishing a causal association will always be difficult. The design of new clinical trials should also take into account the potential for identifying an appropriate nonrandomized cohort receiving the same intervention in which prospective comparisons of outcomes can be made.
Another notable finding from the study by Purvis et al. is that only 5% of patients with stroke consented to take part in clinical studies. This low rate of participation highlights the fact that finding ways to improve participation in clinically useful research remains a priority.
